Global market study: Meningococcal meningitis vaccines

The meningococcal vaccine market is diverse and complex, with regional variations in serogroup distribution, significant use outside of routine immunisation, and 29 marketed products targeting various combinations of the six serogroups (A, B, C, W, X, Y). Discontinued production of polysaccharide vaccines has reduced country access, particularly for MICs. Without increases in production, available supply of conjugate MenACWY will be insufficient to meet demand growth triggered by rising incidence of serogroups C and W and reduced availability of polysaccharide vaccines. LICs, MICs and the Global Stockpile struggle to access multivalent and conjugate vaccines due to limited global access to supply for polysaccharide vaccines as well as high cost for conjugate vaccines. Several multivalent, conjugate vaccines by Indian and Chinese manufacturers are in the pipeline and, if prequalified or registered in many geographies and made available at acceptable prices, could increase global access. The mid- to long-term assessment of this market will be developed following the completion of the Global Roadmap to Defeating Meningitis by 2030.